卵巢癌治療的現況與未來展望

10.6666/ClinMed.201810_82(4).0111

張燕後

化學治療(chemotherapy) ； 標靶治療(targeted therapy) ； 免疫治療(immunotherapy)

臨床醫學月刊

82卷4期（2018 / 10 / 26）

605 - 607

繁體中文

大部分的卵巢癌早期症狀不明顯，發現疾病時已是第三期。適合手術的患者，於首次進行減積手術後，根據病理組織學報告，大多需接受化學治療。無法接受首次手術的患者，可先給予化學治療，再視情況安排減積手術。過去的藥物治療都以化療藥物為主，近年來已有多種標靶藥物通過臨床試驗，可使用於卵巢癌的患者。至於免疫治療藥物的使用，仍處於臨床試驗階段。

1. 衛生福利部國民健康署104年癌症登記年報2017。
2. Chang, YH,Li, WH,Chang, Y(2016).Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.BMC Cancer,16,235.
3. Hamanishi, J,Mandai, M,Ikeda, T(2015).Safety and antitumor activity of antiPD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.J Clin Oncol,33,4015-4022.
4. Kurman, RJ,Shih, IM(2011).Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm.Hum Pathol,42,918-931.
5. Mirza, MR,Monk, BJ,Herrstedt, J(2016).Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.N Engl J Med,375,2154-2164.
6. Shih, IM,Kurman, RJ(2004).Ovarian tumorigenesis- a proposed model based on morphological and molecular genetic analysis.Am J Pathol,164,1511-1518.
7. Varga, A,Piha-Paul, SA,Ott, PA(2015).Antitumor activity and safety of pembrolizumab in patients(pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.J Clin Oncol,33,5510.
8. Vergote, I,Tropé, CG,Amant, F(2010).Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.N Engl J Med,363,943-953.